Loading...
XKRX
099430
Market cap300mUSD
Jun 12, Last price  
7,210.00KRW
Name

BioPlus Co Ltd

Chart & Performance

D1W1MN
XKRX:099430 chart
No data to show
P/E
29.52
P/S
6.29
EPS
244.28
Div Yield, %
Shrs. gr., 5y
18.00%
Rev. gr., 5y
31.30%
Revenues
66.41b
+2.10%
17,020,655,77024,366,600,86037,418,198,22056,718,818,55065,042,901,06066,409,594,580
Net income
14.15b
-44.68%
5,623,358,7009,703,010,83010,724,704,32021,136,873,42025,580,547,16014,151,119,900
CFO
22.29b
+38.96%
4,963,611,42010,043,212,21013,352,359,87013,359,309,38016,040,495,53022,290,031,580
Dividend
Dec 27, 202370 KRW/sh

Profile

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.
IPO date
Sep 27, 2021
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
66,409,595
2.10%
65,042,901
14.68%
56,718,819
51.58%
Cost of revenue
31,833,806
29,866,723
26,708,630
Unusual Expense (Income)
NOPBT
34,575,788
35,176,178
30,010,188
NOPBT Margin
52.06%
54.08%
52.91%
Operating Taxes
153,092
5,318,384
6,763,020
Tax Rate
0.44%
15.12%
22.54%
NOPAT
34,422,696
29,857,794
23,247,169
Net income
14,151,120
-44.68%
25,580,547
21.02%
21,136,873
97.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
(4,990,351)
(4,690,070)
11,292,053
BB yield
1.21%
1.16%
-2.80%
Debt
Debt current
52,911,880
493,508
564,275
Long-term debt
3,225,480
2,619,044
1,128,805
Deferred revenue
Other long-term liabilities
1,484,348
21,793,339
21,798,067
Net debt
8,192,981
(50,850,857)
(23,218,073)
Cash flow
Cash from operating activities
22,290,032
16,040,496
13,359,309
CAPEX
(94,999,393)
(21,092,466)
(6,694,144)
Cash from investing activities
(84,363,787)
21,728,409
(67,130,231)
Cash from financing activities
53,719,014
(14,460,732)
30,659,220
FCF
(33,516,311)
(6,375,723)
6,893,074
Balance
Cash
41,672,524
65,001,777
78,951,329
Long term investments
6,271,854
(11,038,367)
(54,040,176)
Excess cash
44,623,899
50,711,264
22,075,212
Stockholders' equity
122,026,194
108,279,039
78,756,718
Invested Capital
146,005,196
101,380,047
107,743,443
ROIC
27.83%
28.56%
30.79%
ROCE
16.88%
21.67%
22.82%
EV
Common stock shares outstanding
56,556
59,077
58,116
Price
7,310.00
6.40%
6,870.00
-1.01%
6,940.00
0.95%
Market cap
413,423,117
1.86%
405,862,260
0.63%
403,326,650
11.61%
EV
435,869,345
365,256,104
381,803,736
EBITDA
37,845,624
37,666,428
31,897,016
EV/EBITDA
11.52
9.70
11.97
Interest
263,433
60,279
13,304
Interest/NOPBT
0.76%
0.17%
0.04%